| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5892679327a91a1abab5feb5b81042d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2019-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2e579a28cddf2f84e9911df39cc7c7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b09c746c724d822f12b6a75a75b62733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_005c01d5c562a49e73805fa123b9727c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eeabe007ffc0cffaa2b1df7688cdac9 |
| publicationDate |
2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020104777-A1 |
| titleOfInvention |
Compounds for telomere length-related treatment of cancer |
| abstract |
The invention relates to a DNA damage response inhibitor (DDRi) for use, optionally in combination with a DNA damaging agent and/or a DNA damaging procedure, in treating cancer in a patient, characterized in that the patient's cancerous cells have a mean telomere length, determined using high- resolution telomere length analysis, that is less than or equal to a threshold value; and to methods for treating cancer in said patient by administering a DDRi and, optionally in combination with a DNA damaging agent and/or a DNA damaging procedure. |
| priorityDate |
2018-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |